Patents Assigned to Applied Research Systems ARS Holding N.V.
-
Patent number: 7317095Abstract: The inventors have designed novel FSH mutants with increased glycosylation and longer half-lives for use in inducing folliculogenesis in human patients. The use of a FSH mutant preparation of the invention permits the use of lower cumulative doses of FSH to achieve the same or better clinical result.Type: GrantFiled: October 22, 2002Date of Patent: January 8, 2008Assignee: Applied Research Systems ARS Holding N.V.Inventors: William H. Brondyk, Xuliang Jiang, Robert Campbell
-
Patent number: 7317002Abstract: A method is described for the site-specific preparation of hGRF-PEG conjugates containing one or more PEG units (per mole of hGRF) covalently bound to Lys12 and/or Lys21 and/or N?, characterized in that the conjugation reaction between the hGRF peptide and activated PEG is carried out in solution and the desired hGRF-PEG conjugate can be purified by chromatography. The conjugates prepared by this method, as well as their use in the treatment, prevention of diagnosis of growth hormone deficiency, are also an object of the present invention.Type: GrantFiled: December 15, 2004Date of Patent: January 8, 2008Assignee: Applied Research Systems ARS Holding N.V.Inventors: Francesco Maria Veronese, Paolo Caliceti, Oddone Schiavon
-
Publication number: 20070299001Abstract: A process for the purification of recombinant human Chorionic Gonadotropin (hCG) from a sample of crude recombinant hCG in the supernatant of CHO cells comprises the combined use of ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography is performed twice and the final use of a size exclusion chromatography allows the purification from any residual traces of contaminants. The specific bioactivity of the highly purified hCG obtained form the process is particularly high, amounting to about 25,000 IU/mg.Type: ApplicationFiled: August 28, 2007Publication date: December 27, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Gianfranco PARADISI, Mara Rossi, Laura Scaglia
-
Publication number: 20070293422Abstract: Peptides and derivatives or analogs thereof are provided for having ?-amyloid aggregation inhibitory activity, useful in the treatment and prevention of diseases such as Alzheimer's disease, Dementia pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and vascular dementia with amyloid angiopathy.Type: ApplicationFiled: April 29, 2004Publication date: December 20, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Luca Barbero, Pierandrea Esposito, Silvio Traversa
-
Publication number: 20070293555Abstract: The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing various cancers, inflammation, septic shock, preterm labor, infertility, pain, and ischemia, and other diseases and disorders associated with MEK-1 and/or ERK-2 activation.Type: ApplicationFiled: July 24, 2007Publication date: December 20, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Stephen ARKINSTALL, Antonio Arulanandam, Xuliang Jiang, Sharad Magar, Roustem Nabioullin, John Zhang, Peter Blume-Jensen
-
Publication number: 20070280958Abstract: Variants of homodimer-forming chemokines, such as human CCL2, having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds and acting as an obligate monomer, can antagonize natural chemokines and have anti-inflammatory activity in vivo. These variants can be used as active ingredient in pharmaceutical compositions for the treatment of inflammatory, autoimmune, or infectious diseases.Type: ApplicationFiled: October 18, 2004Publication date: December 6, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Amanda Proudfoot, Jeffrey Shaw, Zoe Johnson
-
Publication number: 20070264236Abstract: The present invention provides novel therapeutic molecules called Culling Fusion Proteins (CFPs) that allow the continuous removal of therapeutic targets from extracellular space by exploiting the endosome/lysosome intracellular degradation pathway, and the exocytotic pathway in a combined manner. The products of the invention, by appropriately utilizing the cellular endocytosis and exocytosis mechanism, can be recycled multiple times by cells to eliminate undesired molecules, therefore such therapeutic molecules can be administered at low concentration.Type: ApplicationFiled: August 4, 2004Publication date: November 15, 2007Applicant: Applied Research Systems ARS Holding N.V.Inventor: Meija Yang
-
Publication number: 20070260583Abstract: The present invention relates generally to searching substructures in virtual combinatorial libraries. More precisely, it describes a method of operating a computer for searching substructures in large, non-enumerated virtual combinatorial libraries. Advantageously, the method can return matching products as non-enumerated substructures.Type: ApplicationFiled: March 1, 2005Publication date: November 8, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Daniel Domine, Cedric Merlot
-
Publication number: 20070258962Abstract: The invention relates to an expression vector comprising the promoter of the mCMV-IE2 gene, or a functional expression promoting fragment thereof, and/or an enhancer of the mCMV-IE2 gene, or a functional expression enhancing fragment thereof, wherein expression vector does not contain any complete gene of the mCMV.Type: ApplicationFiled: March 10, 2004Publication date: November 8, 2007Applicant: Applied Research Systems ARS Holding N.V.Inventors: Philippe Chatellard, Markus Imhof
-
Publication number: 20070259892Abstract: The present invention is related to benzazole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such benzazole derivatives. Said benzazole derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK2 and/or 3. The present invention is furthermore related to novel benzazole derivatives as well as to methods of their preparation. X is O, S or NR0, with R0 being H or an unsubstituted or substituted C1-C6 alkyl; G is an unsubstituted or substituted pyrimidinyl group.Type: ApplicationFiled: July 18, 2007Publication date: November 8, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Serge Halazy, Dennis Church, Monstserrat Camps, Pascale Gaillard, Jean-Pierre Gotteland
-
Publication number: 20070249826Abstract: A 21-Hydroxy-6,19-oxidoprogesterone derivative of Formula (1): where R is —C(O)—CH2CH3, —C(O)—(CH2)2—COOH, —C(O)—(CH2)7—CH?CH—(CH2)7—COOH, or —C(O)—PO3Na2.Type: ApplicationFiled: April 12, 2007Publication date: October 25, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Gerardo Burton, Carlos Lantos, Adriana Veleiro
-
Patent number: 7282352Abstract: The present invention relates to a method for improving homogeneity and/or secretion of a recombinant protein of interest expressed in mammalian cells by replacing the endogenous signal peptide sequence of the DNA encoding the protein of interest with that of human hGH. Specifically, the present invention relates to a method wherein the protein of interest is a subunit of the follicle stimulating hormone (FSH). The invention also relates to DNA expression vectors containing the sequence encoding such proteins of interest fused to the signal peptide sequence of the hGH and to cells harbouring such vectors.Type: GrantFiled: June 2, 2004Date of Patent: October 16, 2007Assignee: Applied Research Systems ARS Holding N.V.Inventors: Edith Chitlaru, Hagit Amitai, Daniel Helman
-
Patent number: 7276531Abstract: A gamma-lactam diene of Formula I: which is particularly useful as a medicament for the treatment of various disorders such as asthma, hypertension, osteoporosis, sexual dysfunction and fertility disorders.Type: GrantFiled: March 2, 2004Date of Patent: October 2, 2007Assignee: Applied Research Systems ARS Holding N.V.Inventors: Gian Luca Araldi, Srinivasa Karra, Zhong Zhao, Nadia Brugger
-
Publication number: 20070225202Abstract: The present invention relates to cell-based assays useful for screening for modulators, such as inhibitors, of activated mutant KIT tyrosine kinase receptors, which are associated with mast cell-related disorders, such as mastocytosis and various types of cancer. The invention further provides for the treatment of mast cell-related disorders with an inhibitor identified by the screening method.Type: ApplicationFiled: December 6, 2004Publication date: September 27, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Julian Andreev, Brian Healey, Peter Blume-Jensen, Stephen Arkinstall, Rong Dong
-
Publication number: 20070225214Abstract: The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.Type: ApplicationFiled: February 27, 2007Publication date: September 27, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Ursula Boschert, Georg Feger, Raghuram Selvaraju, Lilia Bernasconi, Ruben Papoian
-
Publication number: 20070224125Abstract: A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.Type: ApplicationFiled: December 21, 2004Publication date: September 27, 2007Applicant: Applied Research Systems ARS Holding N.V.Inventors: Christine Power, Amanda Proudfoot, Achim Frauenschuh
-
Patent number: 7268210Abstract: PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHRH analog administration is beneficial.Type: GrantFiled: May 24, 2005Date of Patent: September 11, 2007Assignee: Applied Research Systems ARS Holding N.V.Inventors: Nabil El-Tayar, Xuan Zhao, Michael D. Bentley
-
Publication number: 20070203134Abstract: The present invention is related to benzimidazole acetonitriles as well as to pharmaceutical formulations containing such benzimidazole acetonitriles of formula (I). Said benzimidazole acetonitriles are useful in the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS) (I). The present invention is furthermore related to methods of preparing benzoxazole acetonitriles. G is pyrimidinyl; L is an amino group, or a 3-8 membered heterocycloalkyl, containing at least one heteroatom selected from N, O, S or L is an acylamino moiety; R1 is selected from the group comprising or consisting of hydrogen, sulfonyl, amino, carboxy, aminocarbonyl, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl or C1-C6-alkoxy, aryl, halogen, cyano or hydroxy; R2 is selected from the group comprising or consisting of hydrogen, C1-C6-alkyl, C2-C6alkenyl, C2-C6-alkynyl, or C1-C6-alkoxy.Type: ApplicationFiled: September 10, 2004Publication date: August 30, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Matthias Schwarz, Pascale Gaillard, Patrick Page, Jean-Pierre Gotteland, Russell Thomas
-
Publication number: 20070197794Abstract: The present invention is related to a new synthesis for preparing pyrrolidine oximes of general formula (I). The compounds of formula (I) are useful in the treatment and/or prevention of preterm labor, premature birth and dysmenorrhea.Type: ApplicationFiled: February 28, 2005Publication date: August 23, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: William Nadler, Doris Pupowicz
-
Patent number: 7258997Abstract: The present invention relates to methods of increasing protein expression levels whereby at least one amino acid in a protein amino acid sequence is substituted for the amino acid, proline. Preferably, the substitution occurs within 15 amino acids, more preferably within 10 amino acids and most preferably within 5 amino acids of a cysteine amino acid residue. The present invention not only includes methods for polypeptides with proline substitutions, but also polynucleotides with codon substitutions for which a codon for any amino acid, except proline, is substituted for a codon encoding for proline.Type: GrantFiled: November 21, 2002Date of Patent: August 21, 2007Assignee: Applied Research Systems Ars Holding N.V.Inventors: William Brondyk, Xuliang Jiang, Rene Lynn Schweickhardt